Wellness testing is the latest countermeasure taken by insurers, employers and governments to keep a lid on exploding healthcare costs. By screening individuals for metabolic efficiency and overall health, those responsible for paying or administering health-related claims get a better handle on risk management and intervention.
Trion Solutions, a leading human resources firm with over 1,000 clients and 15,000 employees, recognizes the importance of screening and recently committed to a pilot program to evaluate the health and economic benefits offered by WellMetris' proprietary Wellness Profile testing platform. WellMetris is a subsidiary of ZIVO Bioscience (OTCQB: ZIVO).
The pilot program with Trion will start with 500 employees. Based on attainment of the price/performance metrics projected by WellMetris, Trion Solutions plans to underwrite a program to test a much larger group of eligible individuals and dependents.
Craig A. Vanderburg, Chief Operating Officer of Trion Solutions, stated, "We are excited about using the WellMetris test to establish a baseline of health for our employees. It's a potential breakthrough that can provide valuable information to the individuals who take the test and the wellness consultants or early intervention providers tasked with improving employee health."
The company's proprietary health and wellness test assesses metabolic status to help focus early intervention and preventative medicine, driving ROI for employers, insurers, and governments. The test is designed to uncover pre-conditions favorable to the onset of disease or impairment usually brought on by unhealthy or stressful lifestyle choices, focusing primarily on the "The Big Four" -- stroke, heart disease, diabetes and cancer.
WellMetris is a breakthrough product, converting expensive lab tests for stress and inflammation into a simple, convenient test that can be performed at the office, on the shop floor or in a retail setting, as well as at clinics and health centers. No other company offers an easy-to-use, cost-effective, and portable wellness test system.
Beyond the blockbuster potential of its human wellness products, ZIVO is also addressing another sizeable market opportunity: animal health.
ZIVO is currently in the concluding stages of its pilot study with Zoetis (NYSE: ZTS), a Pfizer spinoff and the world's largest animal health company. The study is testing a solution to the inflammatory condition known as bovine mastitis, which costs the US dairy industry an estimated $3 billion per year. Globally, this condition is considered the number one health problem affecting the world's 244 million dairy cows. Results from the study are expected in the fourth quarter and option negotiations should begin shortly after.
Since January of 2012, ZIVO has engaged in an aggressive research and validation program to prove the efficacy of its natural products in various applications, from its human wellness tests to bovine udder health and canine joint health.
To better reflect this direction, the company recently changed its name to ZIVO Bioscience. The name and related symbol change represent a milestone in the company's two-plus year transition to a biotech business model where the majority of its revenues will likely be derived from licensing and partnership agreements.
"The name change is both symbolic and practical," stated CEO Andrew Dahl. "It signals a clear break with the past and reflects the effort expended over the last 2-1/2 years in transforming the company into a viable R&D enterprise with significant potential in both nutritional and medical applications."
In addition to its treatment for bovine mastitis, ZIVO is making significant progress in its validation studies for its dietary supplement application for the $300 million canine joint health market. With current studies concluding in late November, ZIVO is expected to enter the next phase of efficacy studies for this application by year end.
As several studies exit their pilot phases, ZIVO is well positioned to partner with global brand names to take its products forward, generating royalty advances and option fee revenue from its near-term licensing opportunities.
ZIVO is yet another example of the great small-cap opportunities we find for you as a member of the RedChip Nation. With two potential blockbuster products addressing $1+ billion market opportunities, we believe ZIVO represents an extremely compelling story with big upside in the near-term.
Visit RedChip.com to learn more about this exciting small-cap stock, and be sure to watch our latest interview with CEO Andrew Dahl. You can also sign up for to receive email alerts and our upcoming research profile on ZIVO.
Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit www.redchip.com/legal/disclosures